Cant

Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis

- Multinational Phase III Study Meets Primary Endpoint inRheumatoid Arthritis Patients Who Failed to Respond to Anti-tumorNecrosis Factor Treatments - NUTLEY, N.J., July 10, 2007 /PRNewswire/ -- Roche todayannounced that results from the Actemra Radiate (RheumAtoiDArthritIs Study in Anti-TNF FailurEs) trial successfully met itsprimary endpoint in patients with moderate to severe rheumatoi...

TMC125 Showed Significant Virologic Response at Week 24 in Treatment-Experienced HIV Patients With NNRTI Resistance in Phase 3 Trials

Data Published in The Lancet on TMC125, an Investigational NNRTIfrom Tibotec YARDLEY, Pa., July 05, 2007 /PRNewswire/ -- Data from twoongoing Phase 3 studies (DUET-1 and DUET-2) showed significantlymore HIV-1 adult patients with documented non-nucleoside reversetranscriptase inhibitor (NNRTI) and protease inhibitor (PI)resistance reached an undetectable viral load (defined as achievingco...

Late Breaking Data Released at ADA Showed that the Investigational Use of Januvia and Metformin as Initial Combination Therapy Provided Significant Glucose Lowering Efficacy over 54 Weeks in Patients with Type 2 Diabetes

CHICAGO--(BUSINESS WIRE)--Jun 23, 2007 - Late breaking datapresented at the American Diabetes Association (ADA) 67th AnnualScientific Sessions showed that, when used investigationally asinitial therapy, JANUVIA(TM) (sitagliptin) in combination withmetformin provided significant glycemic improvement and wasgenerally well tolerated over 54 weeks in patients with type 2diabetes. Additional new...

DiObex Presents Phase 2a Data of DIO-902 Demonstrating Trends of Improved Glycemic Control and Significant Reductions of LDL-Cholesterol and C-Reactive Protein

Top Line Data for the Treatment of Type 2 Diabetes Presented at the67th Annual Scientific Sessions of American Diabetes Association SAN FRANCISCO, June 25, 2007 /PRNewswire/ -- DiObex, Inc., aprivately-held biopharmaceutical company focused on the developmentof therapeutics to treat metabolic diseases, today announced thepresentation of top line data of its phase 2a study of DIO-902, afir...

Neurologix Announces Publication of Landmark Gene Therapy Study Demonstrating Safety and Statistically Significant Improvement in Patients With Advanced Parkinson's Disease

FORT LEE, N.J.--(BUSINESS WIRE)--Jun 21, 2007 - Neurologix, Inc.(OTCBB:NRGX) today announced the publication in the June 23 issueof the journal The Lancet of positive results from the first evergene therapy trial for Parkinson's disease and the first report ofdirect gene transfer into a patient's own brain cells for any adultneurodegenerative disease. The open label Phase 1 study, conduct...

Liraglutide provides significantly better glucose control than insulin glargine in phase 3 study

COPENHAGEN, June 21, 2007-Novo Nordisk today announced clinicalresults from the first of five phase 3 studies with liraglutide -the once-daily human GLP-1 analogue. The 26-week study is part ofthe LEAD(TM) (Liraglutide Effect and Action in Diabetes) programmeand included 581 patients with type 2 diabetes inadequatelycontrolled by two of the most widely used oral antidiabetic drugs:metfor...

Arterial Plaque Significantly Reduced in Women Age 50-59 Taking Hormones, Says New Analysis of Women's Health Initiative Data

Fourth Study to Indicate that Early Use of Estrogen May beCardio-Protective PHOENIX, June 20, 2007 /PRNewswire-USNewswire/ -- A new analysisof Women's Health Initiative data published in the New EnglandJournal of Medicine, shows significant reduction in calcifiedplaque for women aged 50 to 59 using hormone therapy (HT) comparedwith women taking a placebo. This is the first time therelati...

First single breast cancer study to show significant survival benefit for women switching from tamoxifen to Arimidex

Anastrozole (ArimidexTM) improves overall survival inpostmenopausal women with early breast cancer receiving treatmentwith tamoxifen – Survival benefit demonstrated for an AI over tamoxifenin a single trial – LUTON, England, Friday 15 June 2007: Analysis of the entirepopulation of a single trial has demonstrated that survival inearly breast cancer can be signific...

Prexige Study Shows Significantly Less Impact on Blood Pressure Than Ibuprofen in Osteoarthritis Patients with Controlled Hypertension

* New data from 741-patient trial show those treated withPrexige experienced significantly smaller impact on blood pressurecompared to ibuprofen[1] * Many patients with osteoarthritis also have high bloodpressure; even small changes in blood pressure can impactcardiovascular risk[2],[3] * Prexige approved in more than 50 countries and currently underreview in US for use in o...

Lumiracoxib Study Showed Significantly Less Impact on Blood Pressure Than Ibuprofen in Osteoarthritis Patients with Controlled Hypertension

New data From 741-patient Trial Show Those Treated with LumiracoxibExperienced Significantly Smaller Impact on Blood Pressure Comparedto Ibuprofen EAST HANOVER, N.J., June 15, 2007 /PRNewswire/ -- Patients withosteoarthritis who also have controlled hypertension experienced aslight decrease in average daily blood pressure when treated withthe investigational selective COX-2 inhibitor lumi...

Actemra (tocilizumab) Significantly Improves Symptoms of Rheumatoid Arthritis Compared to a Current Standard of Care

NUTLEY, N.J., June 15, 2007 /PRNewswire/ -- Results of theOption (TOcilizumab Pivotal Trial in Methotrexate InadequaterespONders) trial, the first multinational Phase III study outsideof Japan, showed that patients treated with Actemra (either 4mg/kgor 8mg/kg) plus methotrexate achieved a significant and clinicallyimportant improvement in the signs and symptoms of moderate tosevere rheum...

Next Safety, Inc.'s Innovative Drug Delivery System Will Replace Cigarettes and Significantly Advance Pulmonary Medication Delivery

WEST JEFFERSON, N.C.--(BUSINESS WIRE)--Jun 15, 2007 - Next Safety,Inc. has identified basic scientific mechanisms that promise torevolutionize pulmonary drug delivery. This proprietary technologyuses a stream of purified air to deliver medications deep into thepulmonary system. It is considered superior to other drug deliverysystems because it rapidly administers aerosolized drugs to thelin...

Human Genome Sciences Reports That a Phase 2 Study of LymphoStat-B Showed Significant Reductions in Disease Activity in Patients with Active Systemic Lupus Erythematosus

-LymphoStat-B(R) significantly reduced signs and symptoms of SLEdisease at 52 Weeks and demonstrated durable clinical andbiological activity at 76 weeks- ROCKVILLE, Md., June 14, 2007 /PRNewswire-FirstCall/ -- HumanGenome Sciences, Inc. today announced the presentation of Phase 2trial data demonstrating that LymphoStat-B(R) (belimumab)significantly reduced disease activity across multiple...

Neurocrine Biosciences Announces New Research Studies Presented at APSS Reveal Significant Under-Diagnosis of Insomnia

Data Highlights the Impact of Insomnia on Healthcare System andWorker Productivity SAN DIEGO, June 12, 2007 /PRNewswire-FirstCall/ -- NeurocrineBiosciences, Inc. announced today that results from severalresearch studies on the impact of chronic primary and transientinsomnia were presented this week at the Associated ProfessionalSleep Societies (APSS) Annual Meeting. APSS highlights show t...

Ivivi's PEMF Technology Significantly Improves Neuron Survival in Parkinson's Disease Model, Study Finds

NORTHVALE, N.J.--(BUSINESS WIRE)--Jun 12, 2007 - Proprietary PulsedElectromagnetic Field (PEMF) technology, developed by IviviTechnologies, Inc. (AMEX:II), improved neuron survival in astandard animal cell model of brain inflammation, researchersreported today in a platform presentation at theBioelectromagnetics Society (BEMS,http://www.bioelectromagnetics.org) Annual Meeting, in Kanazawa,...

Medivation's Dimebon Maintains Statistically Significant Benefit on All Five Efficacy Endpoints in Alzheimer's Disease Trial After One Year of Therapy

- Aggregate Benefit over Placebo Larger at One Year than at SixMonths - SAN FRANCISCO and WASHINGTON, June 11, 2007/PRNewswire-FirstCall/ -- Medivation, Inc. today announced that thebenefits of Dimebon over placebo in its double-blind,placebo-controlled Phase 2 study in mild-to- moderate Alzheimer'sdisease were statistically significant on all five study endpointsat 12 months. Importantl...

Merck's Investigational Migraine Treatment MK-0974 Significantly Improved Migraine Pain on Several Efficacy Measures in a Phase II Study

CHICAGO--(BUSINESS WIRE)--Jun 7, 2007 - Clinical results from aPhase II study presented for the first time at the AmericanHeadache Society (AHS) annual meeting showed that MK-0974, aninvestigational oral calcitonin gene-related peptide (CGRP)receptor antagonist, significantly improved migraine pain relieftwo hours after dosing compared to placebo, and the relief wassustained through 24 hour...

New Data Confirms Significant Improvement of Disease Signs and Symptoms in Patients with Rheumatoid Arthritis

Second Multinational Phase III Study Provides Further Evidence ofthe Significant Role of IL-6 Receptor Inhibition in the Treatmentof Rheumatoid Arthritis BASEL, Switzerland, June 6, 2007-Roche announced today thatToward (1), the second multinational phase III Actemra(tocilizumab) study, successfully reached its primary endpoint andshowed that a greater proportion of patients treated with...

Interim Data From RECORD Study Show No Significant Difference Between Avandia and Standard Therapy in Risk of Cardiovascular Hospitalization or Death

"Patients and physicians should find these data reassuring" PHILADELPHIA, June 05, 2007 /PRNewswire-FirstCall/ --GlaxoSmithKline said today that findings from an interim analysisof RECORD (Rosiglitazone Evaluated for Cardiac Outcomes andRegulation of glycemia in Diabetes), a prospective clinical trialdesigned specifically to determine cardiovascular outcomes in morethan 4,400 patients wit...

Long-Term Pegylated Interferon Alfa-2b Therapy in Stage III Melanoma Demonstrated Significant and Sustained Impact on Relapse-Free Survival

CHICAGO – June 2, 2007 – Long-term treatment withpegylated interferon alfa-2b in stage III melanoma had asignificant and sustained impact on relapse-free survival (RFS),according to the results of the largest adjuvant trial everconducted in patients with stage III melanoma. Results of the PhaseIII study, led by...

Repros' Androxal Shows Highly Statistically Significant Positive Effects in Men with Secondary Hypogonadism

THE WOODLANDS, Texas--(BUSINESS WIRE)--Jun 5, 2007 - ReprosTherapeutics Inc. (NasdaqGM:RPRX) announced topline results of asix month U.S. Phase 3 study of Androxal(TM), an oral drug beingdeveloped to restore normal testicular function in men withsecondary hypogonadism. Further, Androxal demonstratesnon-inferiority in all the endpoints of the study, compared toAndrogel(R), a cream which is t...

The Eloxatin-Based Regimen (FOLFOX4) Significantly Improved Progression Free Survival When Given Before and After Surgery in Patients With Resectable Liver Metastases From Colorectal Cancer

Presentation at ASCO Plenary Session Reports EORTC 40983 (EPOC)Intergroup Study Results CHICAGO, June 04, 2007 /PRNewswire-FirstCall/ -- Results of therandomized phase III EORTC 40983 Intergroup study, or EPOC study,demonstrate for the first time that peri-operative (pre and postsurgery) FOLFOX4 (Eloxatin(R) (oxaliplatin injection) incombination with a standard chemotherapy regimen for co...

Nexavar Significantly Extends Overall Survival by 44% in Liver Cancer Patients

- First Agent Ever to Demonstrate Significant Survival Benefit inLiver Cancer - CHICAGO, June 04, 2007 /PRNewswire-FirstCall/ -- BayerHealthCare Pharmaceuticals Inc. and Onyx Pharmaceuticals, Inc.today announced that Nexavar(R) (sorafenib) tablets significantlyextended overall survival in patients with hepatocellular carcinoma(HCC), or primary liver cancer versus those taking placebo by 4...

MabThera Significantly Extends Survival And Cures More Patients With Aggressive Lymphoma Than Chemotherapy Alone

Seven year follow up of pivotal trial confirms that more patientsare alive today due to MabThera BASEL, Switzerland, June 4, 2007-A follow-up analysis trackingthe outcome of patients with aggressive non-Hodgkin's lymphoma(NHL) who were treated with the innovative cancer therapy MabThera(rituximab) over seven years ago has revealed exciting results(1). This analysis of the original...

Breaking Multi-Center Study: Masimo SET Pulse Oximetry Technology Shown to Significantly Lower Instances of Severe Retinopathy of Prematurity in Extremely Low Birth Weight Infants

Study released at the Pediatric Academic Societies' Annual MeetingThis Month in Toronto Shows That Switching to Masimo SET PulseOximetry Technology Can Reduce the Risk Associated with ROP by 40% IRVINE, Calif., May 30, 2007 /PRNewswire/ -- Masimo, theinventor of Pulse CO-Oximetry and Read-Through Motion and LowPerfusion pulse oximetry, reported that a new independent studypresented at the...

Daytrana (methylphenidate transdermal system) Provides Significant Effectiveness in ADHD Symptom Relief in Both Boys and Girls

SAN DIEGO, May 23, 2007 /PRNewswire-FirstCall/ -- Shire plcannounced today that DAYTRANA(TM) (methylphenidate transdermalsystem), its Attention Deficit Hyperactivity Disorder (ADHD) patch,had significant efficacy in reducing the symptoms of ADHD in bothmale and female children aged 6 to 12 years, according to clinicaltrial results reported at the American Psychiatric Association(APA) ann...

CEL-SCI'S CEL-1000 Shown to Significantly Enhance Immune Response Against Avian Flu Antigen in Animals

VIENNA, Va., May 23, 2007 /PRNewswire-FirstCall/ -- CEL-SCICORPORATION announces that CEL-1000 increased the immune responseagainst H5 avian influenza antigen in combination with MAS-1, awater-in-oil adjuvant delivery system. These findings werepresented on May 23, 2007 by Dr. Daniel Zimmerman, Senior VicePresident of Research, Cellular Immunology at CEL-SCI at theAmerican Society of Mic...

New Study Suggests no Significant Impairment in Middle-of-the-Night Balance, Mobility or Memory in Older Adults Using Ramelteon

SAN DIEGO, May 22, 2007 /PRNewswire/ -- A new study presentedtoday showed that ramelteon did not impair middle-of-the-nightbalance, mobility or memory performance in older adults withinsomnia, relative to placebo. This study also demonstrated, as inprevious studies, that patients treated with zolpidem did haveimpaired performances on these measures, as compared to placebo.The results of...

Medtronic Updates Long-Term ENDEAVOR I-II Clinical Data Showing Sustained Safety and Significant Reductions in Repeat Procedures

BARCELONA, Spain--(BUSINESS WIRE)--May 22, 2007 - Medtronic(NYSE:MDT) today presented new long-term data from the ENDEAVORclinical trial program reinforcing the existing safety and efficacyprofile of the Endeavor(R) drug-eluting coronary stent system.Four-year results from the 100-patient first-in-man ENDEAVOR Itrial and three-year results from the nearly 1,200 patient ENDEAVORII trial demo...

Auxilium Announces New Data That Show Total Testosterone Blood Levels Increase Significantly Following Switch from AndroGel(R) to Testim(R)

MALVERN, Pa., May 22, 2007 /PRNewswire-FirstCall/ -- AuxiliumPharmaceuticals, Inc. today announced that new data showimprovements in symptoms of decreased libido, energy levels anderectile function in 76 percent of hypogonadal men after switchingbrands of testosterone replacement gel therapy. Total testosteronelevels increased significantly in patients who switched toAuxilium's Testim(R)...

New Analysis of Data Shows Treatment With Abbott's Humira (Adalimumab) Significantly Reduced Disease-Related Hospitalization for Patients with Crohn's Disease

HUMIRA Data Showed 57 Percent Reduction in Risk of Hospitalizationfrom Crohn's Disease vs. Placebo at One Year ABBOTT PARK, Ill., May 22, 2007 /PRNewswire-FirstCall/ -- Abbotttoday announced results from a post-hoc analysis of a pivotal studypresented at the Digestive Disease Week annual meeting inWashington, D.C. showing patients with moderate to severely activeCrohn's disease treated wi...

Pooled Studies Showed Desvenlafaxine Succinate Significantly Improved Painful Symptoms and Anxious Symptoms Associated with Major Depressive Disorder in Adults, Compared With Placebo

Pooled Findings Presented at 2007 APA Meeting Also Showed NoSignificant Impact on Weight for Desvenlafaxine Succinate COLLEGEVILLE, Pa., May 21, 2007 /PRNewswire-FirstCall/ --Findings from two separate pooled analyses - one examining theeffect of desvenlafaxine succinate on anxious symptoms and theother on painful symptoms associated with major depressive disorder(MDD) -- as well as a sep...

Oncophage Cancer Vaccine Significantly Prolongs Recurrence-Free Survival by 45 Percent in Patients With Intermediate-Risk Kidney Cancer

ANAHEIM, Calif.--(BUSINESS WIRE)--May 21, 2007 - Antigenics Inc.(NASDAQ: AGEN) today announced additional follow-up data on thecompany's Phase 3 investigational therapeutic cancer vaccineOncophage(R) (vitespen). The end-of-study results, which reflect anadditional 17 months' data collection, showed that in a substantialsubset of patients (n = 362) at intermediate risk for diseaserecurrence,...

First-of-Its-Kind Study Shows Botox (Botulinum Toxin Type A) Significantly Improves Idiopathic Detrusor Overactivity (IDO) in Patients With Symptoms of Overactive Bladder

Treatment Benefits Were Maintained for at Least 24 Weeks, Accordingto Report Published in The Journal of Urology LONDON, May 15, 2007 /PRNewswire/ -- Researchers from Guy'sHospital and King's College London School of Medicine haveannounced the results from the first randomized, double-blind,placebo-controlled study evaluating botulinum toxin type A (BTX-A,BOTOX(R)) as a treatment for idio...

RTA 402 Shown to Inhibit STAT3 in Animal Model and Holds Significant Promise for Treating Breast Cancer

IRVING, Texas--(BUSINESS WIRE)--May 15, 2007 - ReataPharmaceuticals, Inc. today announced the publication of an articlein the May 2007 issue of the journal Cancer Research showing thatRTA 402, the company's Phase 2 development candidate for cancer,was highly effective in a rigorous animal model of breast cancerand that the drug inhibits signaling activity of STAT3, animportant target for ne...

ISTA Pharmaceuticals Announces Statistically Significant Preliminary Results From its U.S. Phase II/III Clinical Study Of Bepotastine

IRVINE, Calif., May 08, 2007 /PRNewswire-FirstCall/ -- ISTAPharmaceuticals, Inc., today announced results from the preliminaryanalysis of its U.S. Phase II/III clinical study of bepotastine forthe treatment of allergic conjunctivitis. The study evaluated twoconcentrations of bepotastine, each dosed once daily and twicedaily. The primary endpoints of the study were the assessment ofeffica...

Once-yearly Reclast Significantly Reduced Bone Fractures in Women with Postmenopausal Osteoporosis

- Study of over 7,700 women published today shows reduction of 70percent in spine fractures and 41 percent in hip fractures EAST HANOVER, N.J., May 02, 2007 /PRNewswire/ -- A once-yearlytreatment of Reclast(R) (zoledronic acid) Injection significantlyreduced the incidence of all types of osteoporotic bone fracturesover three years in women with postmenopausal osteoporosis. Thisstudy, publ...

Immediate Treatment of Early MS Patients with Betaferon Significantly Delayed Permanent Disability

Risk to confirmed EDSS progression reduced by 40 percent comparedto delayed treatment BERLIN, May 1, 2007 – Bayer Schering Pharma AG,Germany, announced today new data, which show that immediateinitiation of Betaferon® (interferon beta-1b) treatment inpatients with a first event suggestive of multiple sclerosis (MS)can significantly reduce the risk of permanent neurolog...

MabThera Significantly Increases Survival of Lymphoma Patients Regardless of Chemotherapy Regimen

Data published today in the Journal of the National CancerInstitute BASEL, Switzerland, 2 May 2007 - In a study published today inthe Journal of the National Cancer Institute, the innovative cancerdrug MabThera was shown to improve overall survival in patientswith lymphoma regardless of the chemotherapy regimen used.1 Thereview further s...

Lyrica Significantly Reduced Pain and Helped Patients Manage the Symptoms of Fibromyalgia, Data Show

BOSTON--(BUSINESS WIRE)--May 1, 2007 - Significantly more patientstreated with Pfizer's Lyrica reduced their pain by 50 percent ormore compared with placebo, according to study results presentedtoday at the American Academy of Neurology annual meeting.Clinically, this outcome would equate to a patient with severe painreporting a reduction to mild to moderate pain. Fibromyalgia is one of t...